Nonsteroidal anti-inflammatory drug

China Oncology Drugs Market Research Report 2024-2028 Featuring Major Players - Bristol Myers Squibb, Merck, Eli Lilly, Sino BioPharma, F Hoffmann-La Roche, Johnson & Johnson, AbbVie, AstraZeneca - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 20, 2024

High treatment expenses, inadequate insurance, and lack of know-how may also prevent sufferers' capacity to get hold of better oncology treatments in China.

Key Points: 
  • High treatment expenses, inadequate insurance, and lack of know-how may also prevent sufferers' capacity to get hold of better oncology treatments in China.
  • 2.3 Million Oncology deaths are pronounced in China, making Oncology liable for approximately 1 of 5th of all-purpose deaths within the China.
  • NSAIDs (Nonsteroidal Anti-Inflammatory Drugs) and other rising remedies are poised to dominate ChinaOncology drugs market, securing the highest market proportion.
  • This shift signifies a dynamic panorama in China Oncology drugs market, reflecting a growing attention on revolutionary procedures and a broader commitment to preventing oncology comprehensively.

Rebamipide May Combat Low-Grade Inflammation in Post-COVID-19 Syndrome Patients

Retrieved on: 
Monday, February 19, 2024

MILWAUKEE, Feb. 19, 2024 /PRNewswire-PRWeb/ -- Rebamipide may be useful for rehabilitation of patients with SARS-CoV-2 post-COVID syndrome according to new research being presented at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Washington, DC, this month.

Key Points: 
  • "This study revealed higher levels of lipopolysaccharide-binding protein, and lower levels of bacterial permeability protein in patients with post COVID syndrome.
  • Rebamipide, by reducing intestinal permeability, reduces endotoxin load, lowering the level of low-grade inflammation.
  • To explore Rebamipide's usefulness for rehabilitating SARS-CoV-2 post-COVID syndrome patients, researchers examined 62 patients, aged 42-55 years with post-COVID-19 syndrome using nonsteroidal anti-inflammatory drugs for joint pain.
  • Given the effects of SARS-CoV-2 on enterocytes, the results suggest that Rebamipide may be useful for rehabilitation of patients with SARS-CoV-2 post-COVID syndrome.

Premier Diversified Holdings Inc. Announces Cease Trade Order and Provides Update on the Proposed Acquisition of AJA Health and Wellness Ltd., Assured Diagnosis Inc., and AJA Therapeutics Inc.

Retrieved on: 
Monday, February 5, 2024

VANCOUVER, British Columbia, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Premier Diversified Holdings Inc. ("PDH" or the "Company") (TSXV:PDH) announces that further to the press release dated January 18, 2024, whereby the Company announced the filing of an application seeking a management cease trade order (“MCTO”) from the British Columbia Securities Commission (“BCSC”) due to its inability to file its annual financial statements for the year ending September 30, 2023 including the related management’s discussion and analysis and certifications from the CEO and CFO (the “Annual Filings”), the BCSC will issue a cease trade order against PDH (the “CTO”).

Key Points: 
  • The Corporation continues to pursue the acquisitions of AJA Health and Wellness Ltd. ("AJA Health"), AJA Therapeutics Inc. ("ATI"), and Assured Diagnosis Inc. ("ADI", and together with PDH, AJA Health, and ATI, the "Parties").
  • The Acquisition, subject to certain conditions and applicable shareholder and regulatory approvals, will result in a reverse takeover of PDH.
  • There can be no assurance that the Acquisition will be completed as proposed or at all.
  • AJA Health and ADI are diligently working on having audits completed on their financial statements.

Non-Postoperative Acute Pain Treatment Market to Exhibit Enormous Growth During the Study Period (2019-2032) | DelveInsight

Retrieved on: 
Friday, January 26, 2024

LAS VEGAS, Jan. 26, 2024 /PRNewswire/ -- DelveInsight's Non-Postoperative Acute Pain Market Insights report includes a comprehensive understanding of current treatment practices, non-postoperative acute pain emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into the United States.

Key Points: 
  • LAS VEGAS, Jan. 26, 2024 /PRNewswire/ -- DelveInsight's Non-Postoperative Acute Pain Market Insights report includes a comprehensive understanding of current treatment practices, non-postoperative acute pain emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into the United States.
  • Leading non-postoperative acute pain companies such as Vertex Pharmaceuticals, H. Lundbeck A/S, Satsuma Pharmaceuticals, Axsome Therapeutics, Allodynic Therapeutics, and others are developing novel non-postoperative acute pain drugs that can be available in the non-postoperative acute pain market in the coming years.
  • The non-postoperative acute pain epidemiology section provides insights into the historical and current non-postoperative acute pain patient pool and forecasted trends for the US.
  • To know more about non-postoperative acute pain treatment guidelines, visit @ Non-Postoperative Acute Pain Management
    The dynamics of the non-postoperative acute pain market are expected to change in the coming years.

Non-Postoperative Acute Pain Treatment Market to Exhibit Enormous Growth During the Study Period (2019-2032) | DelveInsight

Retrieved on: 
Friday, January 26, 2024

LAS VEGAS, Jan. 26, 2024 /PRNewswire/ -- DelveInsight's Non-Postoperative Acute Pain Market Insights report includes a comprehensive understanding of current treatment practices, non-postoperative acute pain emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into the United States.

Key Points: 
  • LAS VEGAS, Jan. 26, 2024 /PRNewswire/ -- DelveInsight's Non-Postoperative Acute Pain Market Insights report includes a comprehensive understanding of current treatment practices, non-postoperative acute pain emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into the United States.
  • Leading non-postoperative acute pain companies such as Vertex Pharmaceuticals, H. Lundbeck A/S, Satsuma Pharmaceuticals, Axsome Therapeutics, Allodynic Therapeutics, and others are developing novel non-postoperative acute pain drugs that can be available in the non-postoperative acute pain market in the coming years.
  • The non-postoperative acute pain epidemiology section provides insights into the historical and current non-postoperative acute pain patient pool and forecasted trends for the US.
  • To know more about non-postoperative acute pain treatment guidelines, visit @ Non-Postoperative Acute Pain Management
    The dynamics of the non-postoperative acute pain market are expected to change in the coming years.

Heron Therapeutics Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures

Retrieved on: 
Wednesday, January 24, 2024

SAN DIEGO, Jan. 23, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the U.S. Food and Drug Administration (the "FDA") has approved its supplemental New Drug Application ("NDA") for ZYNRELEF® (bupivacaine and meloxicam) extended-release solution to expand the indication for soft tissue and orthopedic surgical procedures including foot and ankle, and other procedures in which direct exposure to articular cartilage is avoided. ZYNRELEF was previously approved for foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures in adults.

Key Points: 
  • ZYNRELEF was previously approved for foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures in adults.
  • This expanded indication for ZYNRELEF will now cover an estimated 13 million procedures annually, an estimated increase of 86% over prior indicated procedures.
  • To obtain this labeling expansion, Heron successfully conducted studies for cesarean section, spinal surgery, augmentation mammoplasty, and total shoulder arthroplasty.
  • The most common side effects of ZYNRELEF are soft tissue procedures: vomiting and orthopedic procedures: constipation and headache.

Osteoarthritis Therapeutics Market to grow by USD 3.96 billion from 2022-2027, North America to account for 32% of market growth - Technavio

Retrieved on: 
Wednesday, January 17, 2024

NEW YORK, Jan. 16, 2024 /PRNewswire/ -- The osteoarthritis therapeutics market size is expected to grow by USD 3.96 billion from 2022 to 2027.

Key Points: 
  • NEW YORK, Jan. 16, 2024 /PRNewswire/ -- The osteoarthritis therapeutics market size is expected to grow by USD 3.96 billion from 2022 to 2027.
  • North America will contribute 32% to the growth of the global market during the forecast period.
  • Such diagnostic advancements not only aid in understanding drug effectiveness but also drive growth in the osteoarthritis therapeutics market.
  • Growth of the osteoarthritis therapeutics market across North America, Europe, Asia, and ROW
    Comprehensive analysis of factors that will challenge the growth of osteoarthritis therapeutics market vendors.

Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030

Retrieved on: 
Tuesday, January 9, 2024

Cancer is a non-treatable chronic disease that has posed a challenge to the medical fraternity for decades.

Key Points: 
  • Cancer is a non-treatable chronic disease that has posed a challenge to the medical fraternity for decades.
  • The entire medical research fraternity has prioritized cancer research in order to find new ways of treatment and analysis.
  • According to Nova one advisor, the global Oncology Cancer Drugs market was valued at USD 147.2 billion in 2021 and it is expected to hit around USD 289.2 billion by 2030 with a CAGR of 8.4% during the forecast period 2022 to 2030.
  • The article continued: “Drugs such as morphine, fentanyl, acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs), and others are used extensively in treating cancer pain in patients with lung cancer, bone cancer, and other types of cancer.

United States Pain Management Therapeutics Market Report 2023: Neurostimulation and Online Pharmacies Surges - Forecasts to 2030 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 9, 2024

The "United States Pain Management Therapeutics Market, Forecast 2023-2030, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "United States Pain Management Therapeutics Market, Forecast 2023-2030, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • The Pain Management Therapeutics Market in the United States demonstrates robust growth, projected to achieve a market size of US$ 33.71 Billion by 2030.
  • The report highlights a substantial investment in research and development by major pharmaceutical organizations to produce advanced pain management solutions.
  • Opioids continue to hold the largest share in the United States pain management drug market.